Product Description: LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC50 value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis[1].
Applications: COVID-19-immunoregulation
Formula: C31H31FN2O7S
References: [1]Chen H, et, al. Discovery of Spiro[pyrrolidine-3,3'-oxindole] LXRβ Agonists for the Treatment of Osteoporosis. J Med Chem. 2023 Jan 12;66(1):752-765.
Molecular Weight: 594.65
Compound Purity: 99.74
Research Area: Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: LXR